- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Alembic Pharmaceuticals Limited — Updates, 19-06-2026: Press Release
19-06-2026 | 01:00 pm
19-06-2026 | 01:00 pm
Alembic Pharma received USFDA tentative approval for Binimetinib Tablets, 45 mg, for melanoma/NSCLC. This targets an estimated US$ 25.9 Cr market and could grant 180 days of generic marketing exclusivity in the US.
No comments yet. Be the first to comment!